Overview

Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness of the sequential therapy with whole lung Lavage (WLL)/inhaling granulocyte-macrophage colony stimulating factor, compared to WLL only, for adult patients with severe autoimmune pulmonary alveolar proteinosis in China over a two-year period.
Phase:
Phase 2
Details
Lead Sponsor:
Dai Huaping